Core Viewpoint - The focus is on producing objective, data-driven research primarily about small- to mid-cap companies, which are often overlooked by many investors, while also occasionally analyzing large-cap companies to provide a broader market perspective [1]. Group 1 - The research emphasizes the importance of small- to mid-cap companies in investment analysis due to their potential for growth and the lack of attention they receive from larger investors [1]. - Large-cap companies are analyzed occasionally to give a comprehensive view of the equity markets, indicating a balanced approach to research [1].

Core Insights - NeuroSense Therapeutics is set to present long-term survival data from its Phase 2b PARADIGM trial of PrimeC for ALS at a scientific conference on March 9, 2026, highlighting a significant 65% reduction in risk of death and a median survival benefit of over 14 months [1][2] Company Overview - NeuroSense Therapeutics is a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's [1] - The company aims to address significant unmet medical needs in neurodegenerative diseases, which currently have limited effective therapeutic options [1] Product Information - PrimeC is NeuroSense's lead drug candidate, an extended-release oral formulation combining two FDA-approved drugs: ciprofloxacin and celecoxib, designed to target multiple mechanisms involved in ALS and Alzheimer's disease [1] - The Phase 2b PARADIGM trial involved 68 ALS patients, demonstrating statistically significant slowing of disease progression and a favorable safety profile over 18 months [1] Clinical Trial Results - The survival analysis from the PARADIGM trial showed a hazard ratio of 0.35 (p=0.0037), indicating a statistically significant reduction in the risk of death after adjusting for baseline risk factors [1] - Kaplan–Meier survival estimates indicated a median survival of 36.3 months for PrimeC compared to 21.4 months for the placebo group (log-rank p=0.0218) [1] Regulatory Engagement - NeuroSense is actively engaging with regulatory authorities to advance PrimeC towards potential marketing authorization, with preparations for a Phase 3 study underway [1]

How much oil do G7 countries hold in emergency reserves? | ReutersSkip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivA pumpjack operates at the Vermilion Energy site in Trigueres, France, June 14, 2024. REUTERS/Benoit Tessier Purchase Licensing Rights, opens new tabPARIS, March 9 (Reuters) - The Group of Seven countries are considering releasing emergency oil stocks to address the Middle Eastern supply crisis, the International Energy Agency sai ...

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Navan, Inc. (NASDAQ: NAVN), its IPO underwriters, and certain executives after the company’s December 15, 2025 announcement of Q3 2026 quarterly financial results for the quarter ended October 31, 2025. Among other matters, investors learned that Navan incurred a huge sequential increase in sales and marketing expenses. Of concern was that the quarter end coincided with Navan’s IPO closing, whereby the ...

Philadelphia, Pennsylvania--(Newsfile Corp. - March 9, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023 through December 26, 2025 (the "Class Period").Investor Deadline: Investors who purchased Ultragenyx common stock during the Class Period may, no later than Apri ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Retirees Are Still Collecting Quarterly Paychecks From An ETF That's Old Enough To Drink - 24/7 Wall St.S&P 5006,693.60 -0.66%Dow Jones47,016.60 -0.90%Nasdaq 10024,550.80 -0.38%Russell 20002,492.26 -1.19%FTSE 10010,211.60 -1.02%Nikkei 22553,408.70 -1.13%Stock Market Live March 9, 2026 – S&P 500 (SPY) Drops as Oil Gushes HigherInvesting# Retirees Are Still Collecting Quarterly Paychecks From An ETF That's Old Enough To Drink### Quick ReadiShares Select Dividend ETF (DVY) yields 3.79%, gained 19% past year an ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

3,327,894+$9.87+6.32%$166.00DowDOW• Vol: 9,148,662+$1.94+5.83%$35.22TeradyneTER• Vol: 1,551,141+$12.04+4.41%$285.09Western DigitalWDC• Vol: 3,199,908+$7.66+3.12%$252.91Occidental PetroleumOXY• Vol: 10,646,295+$1.69+3.12%$55.88## Top Losing StocksUnited AirlinesUAL• Vol: 5,953,445-$5.686.17%$86.39New Pluto GlobalPSKY• Vol: 2,842,134-$0.725.96%$11.28CarnivalCCL• Vol: 17,111,390-$1.515.84%$24.29ExpediaEXPE• Vol: 682,084-$14.025.62%$235.60Stanley Black & DeckerSWK• Vol: 539,231-$4.175.47%$71.92 Goldman Sees $5, ...

New York, NY, March 09, 2026 (GLOBE NEWSWIRE) -- The National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, recommended that T-Mobile US, Inc. discontinue or modify certain express and implied satellite coverage claims for its T Satellite service. The underlying National Advertising Division (NAD) proceeding (Case #7458) was brought by competitor AT&T Services, Inc. NAD found that certain claims related to price increases were supported, while recommending that ot ...